ORPHA:404521
Spinal muscular atrophy with respiratory distress type 2
Also known as: Diaphragmatic spinal muscular atrophy type 2 · SMARD2 · Severe infantile axonal neuropathy with respiratory failure type 2 · X-linked spinal muscular atrophy with respiratory distress
Publications
20
30.9th percentile
Trials
0
Interventional, condition-specific
Researchers
143
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Spinal muscular atrophy with respiratory distress type 2 is a rare, genetic, motor neuron disease characterized by early respiratory failure associated with diaphragm paralysis, distal muscular weakness, joint contractures, and axial with preserved antigravity limb movements. overlaps considerably with SMARD type 1 but is differentiated by a mutation in a different gene.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018450
- UMLS:C4749434
Additional Mondo synonyms (2)
diaphragmatic spinal muscular atrophy type 2 · severe infantile axonal neuropathy with respiratory failure type 2
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
20 matched papers (13 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 166 for broader category spinal muscular atrophy
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
20
20 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
20 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
13 in the last 10 years · high confidence · 30.9th percentile (publications denominator)
Phrase hits: 20 · MeSH hits: 0
Who's working on it?
143
Distinct author names in 20 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Sadowsky CL2 papers · 2023
International Center for Spinal Cord Injury/Kennedy Krieger Institute, Baltimore, Maryland.
Papers in Europe PMC - 02Abboud MR1 paper · 2017
Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Papers in Europe PMC - 03Aggarwal D1 paper · 2021
Department of Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Papers in Europe PMC - 04Angurana SK1 paper · 2021
Department of Pediatrics, Pediatric Emergency and Intensive Care Unit, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Papers in Europe PMC - 05Arkwright PD1 paper · 2017
Department of Paediatric Allergy and Immunology, University of Manchester, Royal Manchester Children's Hospital, Manchester, UK.
Papers in Europe PMC - 06Awano H1 paper · 2024
Organization for Research Initiative and Promotion, Research Initiative Center, Tottori University, 86 Nishi-cho, Yonago 683-8503, Japan.
Papers in Europe PMC - 07Bahrami E1 paper · 2017
Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Papers in Europe PMC - 08Bardhi L1 paper · 2023
Section of Pathology, Department of Medical Biotechnology, University of Siena, 53100 Siena, Italy.
Papers in Europe PMC - 09Barik S1 paper · 2022
Epigenetic and Chromatin Biology Unit, Institute of Life Sciences, Bhubaneswar, India.
Papers in Europe PMC - 10Basu J1 paper · 2022
Epigenetic and Chromatin Biology Unit, Institute of Life Sciences, Bhubaneswar, India.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 166 trials are registered for spinal muscular atrophy, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
166 interventional trials matched spinal muscular atrophy, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: spinal muscular atrophy
166
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07448610·NOT YET RECRUITING·ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)
Conditions: Spinal Muscular Atrophy·Matched via name phrase
- NCT07047144·RECRUITING·A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
Conditions: Spinal Muscular Atrophy · SMA · Spinal Muscular Atrophy Type 2 · Spinal Muscular Atrophy Type 3·Matched via name phrase
- NCT05861986·RECRUITING·A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
Conditions: Muscular Atrophy, Spinal·Matched via name phrase
- NCT07286565·RECRUITING·Active NBS Study: Decentralised Monitoring Motor Development in Children With Duchenne Muscular Dystrophy or Spinal Muscular Atrophy Identified by Newborn Screening
Conditions: Spinal Muscular Atrophy (SMA) · Duchenne Muscular Dystrophy (DMD)·Matched via name phrase
- NCT07321977·RECRUITING·Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic Volunteers
Conditions: Spinal Muscular Atrophy (SMA) · Charcot-Marie-Tooth · Muscular Dystrophy · Myotonic Dystrophy·Matched via name phrase
- NCT07070999·RECRUITING·Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1
Conditions: Spinal Muscular Atrophy Type I·Matched via name phrase
- NCT07287982·RECRUITING·A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
Conditions: Spinal Muscular Atrophy (SMA)·Matched via name phrase
- NCT07554924·RECRUITING·A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
Conditions: Spinal Muscular Atrophy 1·Matched via name phrase
- NCT05866419·RECRUITING·Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
Conditions: Spinal Muscular Atrophy · Spine Deformity · Scoliosis·Matched via name phrase
- NCT07265232·RECRUITING·Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).
Conditions: Spinal Muscular Atrophy (SMA)·Matched via name phrase
- NCT06888661·ENROLLING BY INVITATION·Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy
Conditions: Spinal Muscular Atrophy (SMA)·Matched via name phrase
- NCT07221669·RECRUITING·A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
Conditions: Muscular Atrophy, Spinal·Matched via name phrase
- NCT07332702·RECRUITING·Long Read Analysis in Spinal Muscular Atrophy - LOREASI
Conditions: Spinal Muscular Atrophy (SMA)·Matched via name phrase
- NCT06152302·RECRUITING·Test of Aquatic Mobility of SMA Infants
Conditions: Infantile Spinal Muscular Atrophy·Matched via name phrase
- NCT05824169·RECRUITING·Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients
Conditions: Spinal Muscular Atrophy·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Spinal muscular atrophy with respiratory distress type 2 — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26Likely covered — the policy lists Spinal muscular atrophy as a category (Group 3), and this condition is a form of it. Confirm eligibility with a Centre of Excellence.
Group 3 — high-cost / lifelong therapy with careful selection
Up to ₹50 lakh per patient
Financial support at notified Centres of Excellence is the figure commonly cited in recent MoHFW/PIB statements. Many Group 3 patients also use the MoHFW voluntary-contribution / crowdfunding portal.
Eligibility and patient selection rules change. Verify with a CoE; the crowdfunding portal is a separate mechanism from CoE funding. Verify
Centres of Excellence (15)
- All India Institute of Medical Sciences (AIIMS) — New Delhi, Delhi
- Maulana Azad Medical College — New Delhi, Delhi
- Sanjay Gandhi Post Graduate Institute of Medical Sciences — Lucknow, Uttar Pradesh
- Post Graduate Institute of Medical Education and Research (PGIMER) — Chandigarh, Chandigarh
- Centre for DNA Fingerprinting & Diagnostics with Nizam’s Institute of Medical Sciences — Hyderabad, Telangana
- King Edward Memorial Hospital — Mumbai, Maharashtra
- Institute of Post-Graduate Medical Education and Research (IPGMER) — Kolkata, West Bengal
- Centre for Human Genetics with Indira Gandhi Hospital — Bengaluru, Karnataka
- Institute of Child Health and Hospital for Children (ICH & HC) — Chennai, Tamil Nadu
- All India Institute of Medical Sciences (AIIMS) — Jodhpur, Rajasthan
- Sree Avittam Thirunal Hospital (SAT), Government Medical College — Thiruvananthapuram, Kerala
- All India Institute of Medical Sciences (AIIMS) — Bhopal, Madhya Pradesh
- Regional Institute of Medical Sciences (RIMS) — Imphal, Manipur
- All India Institute of Medical Sciences (AIIMS) — Patna, Bihar
- Assam Medical College & Hospital — Dibrugarh, Assam
Voluntary contributions / crowdfunding (separate from CoE funding): https://rarediseases.mohfw.gov.in/
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Spinal muscular atrophy with respiratory distress type 2" OR "Diaphragmatic spinal muscular atrophy type 2" OR "SMARD2" OR "Severe infantile axonal neuropathy with respiratory failure type 2" OR "X-linked spinal muscular atrophy with respiratory distress"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Spinal muscular atrophy with respiratory distress type 2" OR "Diaphragmatic spinal muscular atrophy type 2" OR "SMARD2" OR "Severe infantile axonal neuropathy with respiratory failure type 2" OR "X-linked spinal muscular atrophy with respiratory distress"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"spinal muscular atrophy"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T15:36:32.213Z
